Home CEL-SCI Corporation

CEL-SCI Corporation

CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection Using its Patented LEAPS Peptide Technology.

The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell-mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it.